Volume 61, Issue 6 pp. 733-742

l-Carnosine: multifunctional dipeptide buffer for sustained-duration topical ophthalmic formulations

Swita R. Singh

Swita R. Singh

Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska

Search for more papers by this author
Samantha T. Carreiro

Samantha T. Carreiro

Department of Ocular Biology, La Jolla Laboratories, San Diego, California, USA

Search for more papers by this author
Jessie Chu

Jessie Chu

Department of Ocular Biology, La Jolla Laboratories, San Diego, California, USA

Search for more papers by this author
Ganesh Prasanna

Ganesh Prasanna

Department of Ocular Biology, La Jolla Laboratories, San Diego, California, USA

Search for more papers by this author
Michael R. Niesman

Michael R. Niesman

Department of Ocular Biology, La Jolla Laboratories, San Diego, California, USA

Search for more papers by this author
Walter W. Collette III

Walter W. Collette III

Department of Drug Safety R&D, La Jolla Laboratories, San Diego, California, USA

Search for more papers by this author
Husam S. Younis

Husam S. Younis

Department of Drug Safety R&D, La Jolla Laboratories, San Diego, California, USA

Search for more papers by this author
Soisurin Sartnurak

Soisurin Sartnurak

Research Science & Technology - Formulations, Pfizer Global Research and Development, La Jolla Laboratories, San Diego, California, USA

Search for more papers by this author
Hovhannes J. Gukasyan

Corresponding Author

Hovhannes J. Gukasyan

Research Science & Technology - Formulations, Pfizer Global Research and Development, La Jolla Laboratories, San Diego, California, USA

1Pfizer Global R&D, La Jolla Laboratories, 10777 Science Center Drive, CB1-1320, San Diego, CA 92121 USA. E-mail: [email protected]Search for more papers by this author
First published: 08 January 2010
Citations: 17

Abstract

Objectives The use of L-carnosine as an excipient in topical ophthalmic formulations containing gellan gum, a carbohydrate polymer with in-situ gelling properties upon mixing with mammalian tear fluid, was developed as a novel platform to extend precorneal duration. Specific utilisation of L-carnosine as a buffer in gellan gum carrying vehicles was characterised.

Methods Buffer capacity was evaluated using 7.5, 13.3, and 44.2 mM L-carnosine in a pH range of 5.5–7.5. Accelerated chemical stability was determined by HPLC at L-carnosine concentrations of 5–100 mM. Combinations of 7.5 mM L-carnosine with 0.06–0.6% (w/v) gellan gum were characterised rheologically. L-Carnosine-buffered solutions of gellan gum were tested for acute topical ocular tolerance in vivo in pigmented rabbits. A unique formulation combining timolol (which lowers intraocular pressure) in L-carnosine-buffered gellan gum was compared with Timoptic-XE in normotensive dogs.

Key findings L-Carnosine exhibited optimal pharmaceutical characteristics for use as a buffer in chronically administered topical ocular formulations. Enhancement trends were observed in solution-to-gel transition of L-carnosine-buffered vehicles containing gellan gum vs comparators. Topical tolerability of L-carnosine-buffered gellan gum formulations and lowering of intraocular pressure were equivalent with timolol and Timoptic-XE.

Conclusions Functional synergy between excipients in gellan gum formulations buffered with L-carnosine has potential for topical ocular dosage forms with sustained precorneal residence.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.